Patent application number | Description | Published |
20100212030 | USE OF N-TERMINAL AND C-TERMINAL PROTEOMICS TECHNOLOGY TO ENHANCE PROTEIN THERAPEUTICS AND DIAGNOSTICS - The present invention provides a novel method for stabilizing proteins, by first identifying the proteolytic sites using N- or C-terminal technology, followed by modification of said sites in order to create stabilized proteins, no longer subject to proteolytic cleavage. the method of the invention immediately provides the user with the exact amino acid position of the proteolytic cleavage site in the protein(s) of interest, even in a complex protein sample. This makes the specific modification of such a site much easier and increases the expectation of success as compared to the amount of effort needed, even in a complex protein sample. | 08-19-2010 |
20100222276 | PROTEASE-SENSITIVE SITE IN APOLIPOPROTEIN A1, THERAPEUTIC AND DIAGNOSTIC IMPLICATIONS - The invention relates to the identification of a naturally occurring internal proteolytic cleavage site in the ApoA1 protein, which leads to inactivation of the mature protein. Specific modification of this cleavage site leads to a stabilised ApoA1 protein, which is beneficial for the reverse cholesterol transport. The invention therefore encompasses pharmaceutical compositions comprising a recombinant stabilised variant ApoA1 protein or rHDL particles comprising such a protein, for use in the treatment of patients having reduced HDL or hampered reverse cholesterol transport. | 09-02-2010 |
20100292131 | BIOMARKERS AND METHODS FOR DIAGNOSING, PREDICTING AND/OR PROGNOSING SEPSIS AND USES THEREOF - The present invention provides kits and methods for the diagnosis, prognosis and prediction of sepsis in a subject or for the differentiation between sepsis and SIRS in a subject, the method comprising(a) measuring the level of pro-hepcidin (pro-HEPC) in a biological sample taken from said subject, (b) measuring the level of at least one further biomarker selected from the group consisting of soluble TNF-receptor 2 (sTNFR2), Pentraxin-3 (PTX-3), Macrophage Colony-Stimulating Factor (MCSF), pro-Brain Natriuretic Protein (pro-BNP), one or more members of the Histone protein family, Procalcitonin (PCT) and c-Reactive Protein (CRP) in a biological sample from said subject, (c) using said measurements obtained in steps (a) and (b) to create a profile for said biomarkers and (d) comparing said profile with a reference biomarker profile obtained form a patient having SIRS or from a healthy subject. | 11-18-2010 |
20100298152 | USE OF APTAMERS IN PROTEOMICS - The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated. | 11-25-2010 |
20100311114 | PREPARATION OF SAMPLES FOR PROTEOME ANALYSIS - The invention mainly concerns methods and systems for the preparation of biological samples for proteome analysis, N-terminal or C-terminal peptides of proteins are enriched using exopeptidase. | 12-09-2010 |
20110237513 | LTBP2 AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 09-29-2011 |
20110251094 | BIOMARKERS FOR HYPERTENSIVE DISORDERS OF PREGNANCY - The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods. | 10-13-2011 |
20110256169 | NOVEL POLYPEPTIDES RELATED TO B-TYPE NATRIURETIC PEPTIDES AND METHODS OF THEIR IDENTIFICATION AND USE - The invention provides novel fragments of proBNP and NTproBNP, particularly useful in prognosing or diagnosing acute heart failure, chronic heart failure or sepsis. | 10-20-2011 |
20110275536 | BIOMARKER FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF ACUTE HEART FAILURE AND USES THEREOF - The application discloses Quiescin Q6 as a new biomarker for acute heart failure; methods for predicting, diagnosing and/or prognosticating acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 11-10-2011 |
20120034240 | PERLECAN AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 02-09-2012 |
20120220493 | BIOMARKER FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF ACUTE HEART FAILURE AND USES THEREOF - The application discloses MCAM as a new biomarker for acute heart failure; methods for predicting, diagnosing, prognosticating and/or monitoring acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 08-30-2012 |
20120237962 | MCAM AS A BIOMARKER FOR FLUID HOMEOSTASIS - The application discloses MCAM as a new biomarker for fluid homeostatic imbalance; methods for predicting, diagnosing, prognosticating and/or monitoring fluid homeostatic imbalance based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 09-20-2012 |
20130040881 | LTBP2 AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. LTBP2 is also involved in glomerular filtration rate, dyspnea, acute heart failure, left ventricular hypertrophy, cardiac fibrosis, preeclampsia, pregnancy- associated proteinuria. | 02-14-2013 |
20130045889 | BIOMARKERS FOR HYPERTENSIVE DISORDERS OF PREGNANCY - The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods. | 02-21-2013 |
20130116151 | BIOMARKER FOR HYPERTENSIVE DISORDERS OF PREGNANCY - The application discloses a new tool for predicting, diagnosing and prognosing hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders; and kits and devices for measuring said biomarker and/or performing said methods. | 05-09-2013 |
20130129750 | PERLECAN AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 05-23-2013 |
20130150282 | LTBP2 AS A BIOMARKER FOR EVALUATING THE RISK OF DEATH IN A DISEASED SUBJECT - The application discloses methods for treating a subject presenting with one or more signs of an inflammatory condition, or methods for evaluating the risk of death within a year for a subject presenting with one or more signs of an inflammatory condition, based on measuring the quantity of LTBP2 in a sample from the subject; and kits and devices for measuring LTBP2 and/or performing said methods. | 06-13-2013 |
20140113308 | MCAM AS A BIOMARKER FOR FLUID HOMEOSTASIS - The application discloses MCAM as a new biomarker for fluid homeostatic imbalance; methods for predicting, diagnosing, prognosticating and/or monitoring fluid homeostatic imbalance based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 04-24-2014 |
20140236833 | TRANSACTION METHOD BASED ON THE GENETIC IDENTITY OF AN INDIVIDUAL AND TOOLS RELATED THEREOF - The current invention relates to a method for establishing a transaction between an individual and a third party, based on the genetic identity of an individual, characterized in that said individual allows third party to access and analyze only a subset of said genetic identity, required for the offer and establishment of the transaction. In a second aspect, the invention discloses tools for the analysis of the genetic identity of individuals. | 08-21-2014 |
20140302509 | PROCATHEPSIN L AND CATHEPSIN L AS BIOMARKERS FOR ISCHEMIA - The present invention relates to procathepsin L, cathepsin L or a fragment thereof as a biomarker for ischemia. The present invention further relates to methods for diagnosing, predicting, prognosticating and/or monitoring ischemia based on measuring said biomarker, and to related kits, devices and uses thereof. | 10-09-2014 |
20150087536 | USE OF APTAMERS IN PROTEOMICS - The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated. | 03-26-2015 |